153 related articles for article (PubMed ID: 38734640)
1. Erianin inhibits the progression of triple-negative breast cancer by suppressing SRC-mediated cholesterol metabolism.
Li M; Kang S; Deng X; Li H; Zhao Y; Tang W; Sheng M
Cancer Cell Int; 2024 May; 24(1):166. PubMed ID: 38734640
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of Erianin anti-triple negative breast cancer based on transcriptomics methods and network pharmacology.
Li M; Zhao Y; Li H; Kang S; Deng X; Sheng M
Aging (Albany NY); 2024 Feb; 16(3):2848-2865. PubMed ID: 38329441
[TBL] [Abstract][Full Text] [Related]
3. Erianin induces triple-negative breast cancer cells apoptosis by activating PI3K/Akt pathway.
Xu Y; Fang R; Shao J; Cai Z
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34036307
[TBL] [Abstract][Full Text] [Related]
4. Erianin, the main active ingredient of Dendrobium chrysotoxum Lindl, inhibits precancerous lesions of gastric cancer (PLGC) through suppression of the HRAS-PI3K-AKT signaling pathway as revealed by network pharmacology and in vitro experimental verification.
Wang Y; Chu F; Lin J; Li Y; Johnson N; Zhang J; Gai C; Su Z; Cheng H; Wang L; Ding X
J Ethnopharmacol; 2021 Oct; 279():114399. PubMed ID: 34246740
[TBL] [Abstract][Full Text] [Related]
5. Erianin inhibits the proliferation of T47D cells by inhibiting cell cycles, inducing apoptosis and suppressing migration.
Sun J; Fu X; Wang Y; Liu Y; Zhang Y; Hao T; Hu X
Am J Transl Res; 2016; 8(7):3077-86. PubMed ID: 27508028
[TBL] [Abstract][Full Text] [Related]
6. Erianin inhibits human lung cancer cell growth via PI3K/Akt/mTOR pathway in vitro and in vivo.
Zhang HQ; Xie XF; Li GM; Chen JR; Li MT; Xu X; Xiong QY; Chen GR; Yin YP; Peng F; Chen Y; Peng C
Phytother Res; 2021 Aug; 35(8):4511-4525. PubMed ID: 34236105
[TBL] [Abstract][Full Text] [Related]
7. c-Src inhibitor selectively inhibits triple-negative breast cancer overexpressed Vimentin in vitro and in vivo.
Lou L; Yu Z; Wang Y; Wang S; Zhao Y
Cancer Sci; 2018 May; 109(5):1648-1659. PubMed ID: 29575318
[TBL] [Abstract][Full Text] [Related]
8. Erianin promotes apoptosis and inhibits Akt-mediated aerobic glycolysis of cancer cells.
Han S; Chen S; Wang J; Huang S; Xiao Y; Deng G
J Cancer; 2024; 15(8):2380-2390. PubMed ID: 38495480
[TBL] [Abstract][Full Text] [Related]
9. UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer.
Gilani RA; Phadke S; Bao LW; Lachacz EJ; Dziubinski ML; Brandvold KR; Steffey ME; Kwarcinski FE; Graveel CR; Kidwell KM; Merajver SD; Soellner MB
Clin Cancer Res; 2016 Oct; 22(20):5087-5096. PubMed ID: 27154914
[TBL] [Abstract][Full Text] [Related]
10. Ethyl acetate extract of Antenoron Filiforme inhibits the proliferation of triple negative breast cancer cells via suppressing Skp2/p21 signaling axis.
Liao Y; Li S; An J; Yu X; Tan X; Gui Y; Wang Y; Huang L; Zhou S; Wang D
Phytomedicine; 2023 Jul; 116():154856. PubMed ID: 37187035
[TBL] [Abstract][Full Text] [Related]
11. Curcumin and its nano-formulations: Defining triple-negative breast cancer targets through network pharmacology, molecular docking, and experimental verification.
Deng Z; Chen G; Shi Y; Lin Y; Ou J; Zhu H; Wu J; Li G; Lv L
Front Pharmacol; 2022; 13():920514. PubMed ID: 36003508
[No Abstract] [Full Text] [Related]
12. XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer.
Xu S; Sun X; Luo L; Yang Y; Guo Q; Tang S; Jiang Z; Li Y; Han J; Gan W; Yang F; Zhang X; Liu Y; Sun C; He J; Liu M; Zuo D; Zhu W; Wu Y
Biomed Pharmacother; 2022 Nov; 155():113537. PubMed ID: 36113258
[TBL] [Abstract][Full Text] [Related]
13. Anticancer Activity of Erianin: Cancer-Specific Target Prediction Based on Network Pharmacology.
Yan L; Zhang Z; Liu Y; Ren S; Zhu Z; Wei L; Feng J; Duan T; Sun X; Xie T; Sui X
Front Mol Biosci; 2022; 9():862932. PubMed ID: 35372513
[TBL] [Abstract][Full Text] [Related]
14. Erianin serves as an NFATc1 inhibitor to prevent breast cancer-induced osteoclastogenesis and bone destruction.
Zheng J; He W; Chen Y; Li L; Liang Q; Dai W; Li R; Chen F; Chen Z; Tan Y; Li X
J Adv Res; 2024 Mar; ():. PubMed ID: 38556044
[TBL] [Abstract][Full Text] [Related]
15. A chalcone-syringaldehyde hybrid inhibits triple-negative breast cancer cell proliferation and migration by inhibiting CKAP2-mediated FAK and STAT3 phosphorylation.
Jin XX; Mei YN; Shen Z; Zhu JF; Xing SH; Yang HM; Liang G; Zheng XH
Phytomedicine; 2022 Jul; 101():154087. PubMed ID: 35429924
[TBL] [Abstract][Full Text] [Related]
16. Dual Targeting of Cell Growth and Phagocytosis by Erianin for Human Colorectal Cancer.
Sun Y; Li G; Zhou Q; Shao D; Lv J; Zhou J
Drug Des Devel Ther; 2020; 14():3301-3313. PubMed ID: 32848368
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP).
Qian XL; Zhang J; Li PZ; Lang RG; Li WD; Sun H; Liu FF; Guo XJ; Gu F; Fu L
PLoS One; 2017; 12(1):e0171169. PubMed ID: 28141839
[TBL] [Abstract][Full Text] [Related]
18. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
[TBL] [Abstract][Full Text] [Related]
19. β, β-Dimethylacrylshikonin potentiates paclitaxel activity, suppresses immune evasion and triple negative breast cancer progression via STAT3Y705 phosphorylation inhibition based on network pharmacology and transcriptomics analysis.
Wu Z; Wu H; Wang Z; Li H; Gu H; Xia E; Yan C; Dai Y; Liu C; Wang X; Lv L; Bao J; Wang O; Dai X
Phytomedicine; 2023 Jun; 114():154769. PubMed ID: 36940580
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic adenovirus encoding apolipoprotein A1 suppresses metastasis of triple-negative breast cancer in mice.
Dong J; Kong L; Wang S; Xia M; Zhang Y; Wu J; Yang F; Zuo S; Wei J
J Exp Clin Cancer Res; 2024 Apr; 43(1):102. PubMed ID: 38566092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
